September 22, 2011

European Medicines Agency (EMA) confirms positive benefit-risk balance for Multaq®

- European Prescribing Information Updated to Ensure Multaq® Use in Appropriate Paroxysmal and Persistent AF Patients -

 

European Medicines Agency (EMA) confirms positive benefit-risk balance for Multaq®
- European Prescribing Information Updated to Ensure Multaq® Use in Appropriate Paroxysmal and Persistent AF Patients -

Paris, France – September 22, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed a positive benefit-risk balance for Multaq® (dronedarone) for the treatment of a newly defined population of paroxysmal and persistent Atrial Fibrillation (AF) patients, following its review under the Article 20 procedure.